➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
McKesson
Baxter
Mallinckrodt
Colorcon

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ICODEXTRIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Icodextrin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004987 ↗ Treatment of Advanced AIDS Patients With Dextrin Sulfate Unknown status Steinhart Medical Associates Phase 1 1999-10-01 The purpose of this study is to look at the safety and effectiveness of dextrin sulfate in AIDS patients who have failed conventional anti-HIV treatment.
NCT00119990 ↗ Changes in Cardiovascular Hemodynamics During Peritoneal Dialysis Terminated University of Aarhus N/A 2006-01-01 During peritoneal dialysis, water is removed from the body. This sometimes occurs at rates of up to 500 ml/h. During shifts with dialysate with high glucose content, an increase in blood pressure has been described. The effect upon central hemodynamics is unknown. The researchers are investigating the effects of low and high glucose dialysate and icodextrin on cardiac output, stroke volume, pulse rate and blood pressure. The researchers have hypothesized that the effects seen are induced by vasopressin.
NCT00369096 ↗ Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina) Completed Infociencia S.L Phase 2 2006-09-01 The purpose of this study is to evaluate whether addition of bemiparin, once daily in icodextrin solution for peritoneal dialysis for 16 weeks, increases the peritoneal capacity for ultrafiltration and/or reduces creatinine transport in peritoneal dialysis patients presenting functional disorders related to ultrafiltration deficit and/or high transport.
NCT00369096 ↗ Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina) Completed Fundación Renal Iñigo Alvarez De Toledo Phase 2 2006-09-01 The purpose of this study is to evaluate whether addition of bemiparin, once daily in icodextrin solution for peritoneal dialysis for 16 weeks, increases the peritoneal capacity for ultrafiltration and/or reduces creatinine transport in peritoneal dialysis patients presenting functional disorders related to ultrafiltration deficit and/or high transport.
NCT00397358 ↗ Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients Terminated Baxter Healthcare Corporation Phase 4 2006-11-01 This is a Phase IV study evaluating triglyceride levels in peritoneal dialysis patients.
NCT00725517 ↗ Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange Completed Shanghai Jiao Tong University School of Medicine Phase 4 2005-12-01 The purpose of this study is to evaluate the efficacy and safety of a 7.5% Icodextrin peritoneal dialysis solution for once-daily long dwell exchange in patients undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD) in Chinese uremic patients.Patients were divided into Dianeal group or Extraneal group for long dwell time. Net ultrafiltration, small solute clearance and relationship between different transport group were used to evaluate efficacy of Icodextrin. Physical examination, vital signs and laboratory tests were used to evaluate safety of Icodextrin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Icodextrin

Condition Name

Condition Name for Icodextrin
Intervention Trials
End Stage Renal Disease 4
Peritoneal Dialysis 3
HIV Infections 1
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Icodextrin
Intervention Trials
Kidney Failure, Chronic 5
Peritonitis 2
Heart Failure 1
Renal Insufficiency, Chronic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Icodextrin

Trials by Country

Trials by Country for Icodextrin
Location Trials
Spain 5
United States 5
Korea, Republic of 2
Hong Kong 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Icodextrin
Location Trials
Pennsylvania 1
Nebraska 1
Indiana 1
California 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Icodextrin

Clinical Trial Phase

Clinical Trial Phase for Icodextrin
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 2 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Icodextrin
Clinical Trial Phase Trials
Completed 4
Recruiting 4
Unknown status 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Icodextrin

Sponsor Name

Sponsor Name for Icodextrin
Sponsor Trials
Baxter Healthcare Corporation 4
Iperboreal Pharma Srl 2
Chinese University of Hong Kong 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Icodextrin
Sponsor Trials
Other 13
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.